Skip to main content

Table 1 Demographic and Baseline Characteristics According to DB Randomization (OLE Safety Analysis Set)

From: Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

 

Placeboa(n = 262)

Quarterly fremanezumaba(n = 271)

Monthly fremanezumaba(n = 274)

Total(n = 807)

Age, mean (SD), years

46.9 (11.2)

46.0 (11.0)

46.1 (11.0)

46.4 (11.0)

Female sex, n (%)

218 (83)

226 (83)

230 (84)

674 (84)

Race, n (%)

 White

247 (94)

258 (95)

254 (93)

759 (94)

 Black/African American

1 (<1)

1 (<1)

4 (1)

6 (<1)

 Asian

1 (<1)

0

2 (<1)

3 (<1)

 American Indian or Alaska Native

0

0

1 (<1)

1 (<1)

 Other

1 (<1)

2 (<1)

1 (<1)

4 (<1)

 Not reported

12 (5)

10 (4)

12 (4)

34 (4)

Weight, mean (SD), kg

71.3 (13.9)

70.5 (13.3)

71.1 (13.8)

71.0 (13.7)

Height, mean (SD), cm

167.6 (9.0)

167.6 (7.9)

167.4 (7.6)

167.6 (8.2)

Body mass index, mean (SD), kg/m2

25.3 (4.1)

25.0 (4.1)

25.3 (4.4)

25.2 (4.2)

Years since initial migraine diagnosis, mean (SD)

24.3 (13.4)

24.4 (12.9)

24.3 (13.7)

24.3 (13.3)

Migraine classification, n (%)

 Episodic migraine

105 (40)

102 (38)

106 (39)

313 (39)

 Chronic migraine

157 (60)

169 (62)

168 (61)

494 (61)

Number of prior preventive medications failed, n (%)

 2

131 (50)

138 (51)

129 (47)

398 (49)

 3

77 (29)

82 (30)

94 (34)

253 (31)

 4

54 (21)

49 (18)

49 (18)

152 (19)

Monthly average number of migraine days, mean (SD)b

14.4 (6.2)

14.2 (5.6)

14.0 (5.5)

14.2 (5.8)

Headache days of at least moderate severity, mean (SD)b

12.9 (5.9)

12.5 (5.8)

12.6 (5.7)

12.7 (5.8)

Days per month of acute headache medication use, mean (SD)b

12.4 (6.3)

12.9 (6.2)

12.1 (5.9)

12.5 (6.1)

Days per month with photophobia/phonophobia, mean (SD)b

9.9 (7.8)

9.5 (6.8)

9.4 (6.8)

9.6 (7.2)

Days per month with nausea/vomiting, mean (SD)b

6.4 (6.0)

6.7 (5.9)

6.6 (5.9)

6.5 (5.9)

HIT-6 score, mean (SD)b

64.1 (4.8)

64.3 (4.3)

63.9 (4.5)

64.1 (4.5)

MIDAS score, mean (SD)b

62.0 (57.4)

62.2 (49.3)

61.8 (51.3)

62.0 (50.6)

  1. DB double-blind, OLE open-label extension, SD standard deviation, HIT-6 6-item Headache Impact Test, MIDAS Migraine Disability Assessment, mITT modified intent-to-treat
  2. aAll patients in the OLE received fremanezumab 225 mg monthly
  3. bOLE mITT analysis set